IL162167A0 - Metabolites of (3-äÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylü-phenoxy)-acetic acid - Google Patents

Metabolites of (3-äÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylü-phenoxy)-acetic acid

Info

Publication number
IL162167A0
IL162167A0 IL16216703A IL16216703A IL162167A0 IL 162167 A0 IL162167 A0 IL 162167A0 IL 16216703 A IL16216703 A IL 16216703A IL 16216703 A IL16216703 A IL 16216703A IL 162167 A0 IL162167 A0 IL 162167A0
Authority
IL
Israel
Prior art keywords
methylü
aminoü
metabolites
sulfonyl
phenoxy
Prior art date
Application number
IL16216703A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL162167A0 publication Critical patent/IL162167A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL16216703A 2002-01-31 2003-01-20 Metabolites of (3-äÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylü-phenoxy)-acetic acid IL162167A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35374802P 2002-01-31 2002-01-31
PCT/IB2003/000121 WO2003064391A1 (en) 2002-01-31 2003-01-20 Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid

Publications (1)

Publication Number Publication Date
IL162167A0 true IL162167A0 (en) 2005-11-20

Family

ID=27663249

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16216703A IL162167A0 (en) 2002-01-31 2003-01-20 Metabolites of (3-äÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylü-phenoxy)-acetic acid

Country Status (29)

Country Link
US (1) US6852863B2 (es)
EP (1) EP1470109A1 (es)
JP (1) JP2005521668A (es)
KR (1) KR20040077884A (es)
CN (1) CN1625549A (es)
AP (1) AP2004003094A0 (es)
AR (1) AR038332A1 (es)
BR (1) BR0307339A (es)
CA (1) CA2473984A1 (es)
EA (1) EA200400724A1 (es)
EC (1) ECSP045215A (es)
GB (1) GB2400100B (es)
HN (1) HN2003000051A (es)
HR (1) HRP20040683A2 (es)
HU (1) HUP0500012A2 (es)
IL (1) IL162167A0 (es)
IS (1) IS7281A (es)
MA (1) MA27169A1 (es)
MX (1) MXPA04004960A (es)
NO (1) NO20043569L (es)
OA (1) OA12760A (es)
PA (1) PA8564601A1 (es)
PE (1) PE20030978A1 (es)
PL (1) PL371982A1 (es)
TN (1) TNSN04138A1 (es)
TW (1) TW200302080A (es)
UY (1) UY27632A1 (es)
WO (1) WO2003064391A1 (es)
ZA (1) ZA200404067B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
TWI332937B (en) * 2005-04-20 2010-11-11 Lg Chemical Ltd Additive for non-aqueous electrolyte and secondary battery using the same
EA200970067A1 (ru) * 2006-07-28 2009-08-28 Пфайзер Продактс Инк. Агонисты ep2
CA2679882C (en) 2007-03-08 2015-12-29 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
DK2264009T3 (en) * 2008-03-12 2019-04-15 Ube Industries PYRIDYLAMINE ACEDIC ACID COMPOUND
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
CA2757291C (en) 2009-03-30 2017-05-23 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of glaucoma
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
EP1470109A1 (en) 2004-10-27
KR20040077884A (ko) 2004-09-07
WO2003064391A1 (en) 2003-08-07
PE20030978A1 (es) 2003-11-19
MXPA04004960A (es) 2005-04-08
EA200400724A1 (ru) 2004-12-30
TW200302080A (en) 2003-08-01
US20030216445A1 (en) 2003-11-20
TNSN04138A1 (fr) 2007-03-12
GB0413967D0 (en) 2004-07-28
AP2004003094A0 (en) 2004-09-30
NO20043569D0 (no) 2004-08-26
PA8564601A1 (es) 2003-09-05
JP2005521668A (ja) 2005-07-21
GB2400100A (en) 2004-10-06
IS7281A (is) 2004-05-21
AR038332A1 (es) 2005-01-12
MA27169A1 (fr) 2005-01-03
HUP0500012A2 (hu) 2005-04-28
GB2400100B (en) 2006-04-12
PL371982A1 (en) 2005-07-11
BR0307339A (pt) 2004-12-07
ECSP045215A (es) 2004-09-28
HN2003000051A (es) 2003-09-24
OA12760A (en) 2006-07-04
US6852863B2 (en) 2005-02-08
NO20043569L (no) 2004-08-26
CN1625549A (zh) 2005-06-08
UY27632A1 (es) 2003-08-29
HRP20040683A2 (en) 2004-10-31
CA2473984A1 (en) 2003-08-07
ZA200404067B (en) 2005-08-29

Similar Documents

Publication Publication Date Title
EG23458A (en) Set of elements for assemlying structures
IL162167A0 (en) Metabolites of (3-äÄ4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-aminoÜ-methylü-phenoxy)-acetic acid
HK1077762A1 (zh) TFGß[轉化生長因子]的抑制劑
AU2003236991A8 (en) Representations of processes
AU2002334321A1 (en) Method for the production of phytoalexins
IL164645A0 (en) Polymorph of 4-Ä2-Ä1-(2-ethoxyethyl)-1H-benzidimazole-2-YLÜ-1-piperidinylÜethylÜ-??-dimethyl-benzenoacetic acid
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
AU2003253918A8 (en) Methods of modifying behavior of cd9-expressing cells
PL371427A1 (en) New uses of substituted aminoalkanephosphonic acids
GB0230240D0 (en) Removal of an acid
HK1075885A1 (en) 20-Hydroxyeicosatetraenoic acid production inhibitors
AU2003233068A1 (en) Core-assisted formation of microcapsules
AU2003299746A1 (en) Total synthesis of daurichromenic acid
AU2002253633A1 (en) 20-hydroxyeicosatetraenoic acid production inhibitors
AU2003231527A8 (en) Novel derivatives of carnosic acid
IL166778A0 (en) Derivatives of gl ycinergic r(+)-2-amino-3-hydroxypropanoic acid
AU2003240137A1 (en) Novel phosphonocarboxylic acid esters
HK1078562A1 (en) Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2- methylhept-5-enoic acid
GB0312028D0 (en) Manufacture of signs
TW592379U (en) Improved structure of transformer
AU2002259127A1 (en) Synthesis of 4-phenylbutyric acid
TW529396U (en) Structure suitable for variety of lanterns
PL358045A1 (en) Set of transformer terminals
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40
PL355037A1 (en) New method of manufacture of olanzapine